Community Acquired Pneumonia Risk Assessment
37 Questions
5 Views

Community Acquired Pneumonia Risk Assessment

Created by
@RefreshedTsavorite

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

Which cell type predominates during the resolution phase of pneumonia?

  • Neutrophils
  • Red Blood Cells
  • Bacteria
  • Macrophages (correct)
  • What is the initial phase of classic lobar pneumonia characterized by?

  • Gray hepatization
  • Edema (correct)
  • Resolution
  • Red hepatization
  • Which phase corresponds to the successful containment of infection with improved gas exchange?

  • Resolution
  • Edema
  • Gray hepatization (correct)
  • Red hepatization
  • In the context of pneumonia, what is the dominant cell type during the red hepatization phase?

    <p>Red Blood Cells</p> Signup and view all the answers

    What is the typical radiograph pattern observed in bacterial community-acquired pneumonia (CAP)?

    <p>Lobar pneumonia</p> Signup and view all the answers

    Which vital sign indicates a risk factor for High-Risk Community Acquired Pneumonia (CAP)?

    <p>Respiratory rate of 28/min</p> Signup and view all the answers

    Which of the following pathogens is classified under Low Risk for CAP?

    <p><em>Streptococcus pneumoniae</em></p> Signup and view all the answers

    What condition must be met for moderate-risk CAP to be considered?

    <p>Presence of <em>Legionella pneumophila</em></p> Signup and view all the answers

    Which symptom is least likely associated with Community Acquired Pneumonia?

    <p>Significant weight gain</p> Signup and view all the answers

    Which physical examination finding is indicative of severe CAP?

    <p>Dull to flat percussion note</p> Signup and view all the answers

    What is a common clinical finding that helps differentiate CAP from other infections?

    <p>Pleuritic chest pain</p> Signup and view all the answers

    Which of the following scenarios increases the risk for anaerobic infection in pneumonia?

    <p>Stroke or decreased consciousness</p> Signup and view all the answers

    What is the recommended action for a patient presenting with severe sepsis due to pneumonia?

    <p>Admit to the ICU for monitoring</p> Signup and view all the answers

    What is the most common cause of community-acquired pneumonia (CAP)?

    <p>Streptococcus pneumoniae</p> Signup and view all the answers

    Which of the following characteristics is typical of atypical pneumonia?

    <p>Dry cough with significant extrapulmonary symptoms</p> Signup and view all the answers

    Which organism is often associated with pneumonia following influenza infections?

    <p>Staphylococcus aureus</p> Signup and view all the answers

    What diagnostic test is considered the best initial evaluation for pneumonia?

    <p>Chest x-ray</p> Signup and view all the answers

    Which of the following biomarkers is NOT mentioned as useful in assessing pneumonia severity?

    <p>Blood urea nitrogen (BUN)</p> Signup and view all the answers

    Which of the following statements about atypical organisms of CAP is correct?

    <p>They cannot be easily cultured on standard media or Gram stain.</p> Signup and view all the answers

    What respiratory condition is associated with the pathogen Pseudomonas aeruginosa?

    <p>Chronic obstructive pulmonary disease (COPD)</p> Signup and view all the answers

    Which agent is associated with pneumonia in individuals who have been exposed to birds?

    <p>Chlamydia psittaci</p> Signup and view all the answers

    What is the drug of choice for low-risk patients with no co-morbid illness?

    <p>Amoxicillin</p> Signup and view all the answers

    In moderate-risk patients without a risk for Pseudomonas, which combination of treatments is appropriate?

    <p>IV non-antipseudomonal B-lactam + IV extended macrolide</p> Signup and view all the answers

    What should be expected as the first sign of response to treatment?

    <p>Resolution of fever</p> Signup and view all the answers

    Which of the following is NOT a reason for lack of response to treatment?

    <p>Adequate antibiotic dose</p> Signup and view all the answers

    For most bacterial pneumonias except enteric Gram-negative pathogens, what is the recommended duration of therapy?

    <p>5-7 days</p> Signup and view all the answers

    What is the recommended treatment addition for high-risk patients with suspected MRSA?

    <p>Vancomycin</p> Signup and view all the answers

    How long should most symptoms resolve within effective treatment?

    <p>3 months</p> Signup and view all the answers

    Which of the following could be a reason for treating with a B-lactam/BLIC combination in stable co-morbid patients?

    <p>Presence of co-morbid illness</p> Signup and view all the answers

    How long should a patient with MSSA/Staph aureus pneumonia be treated?

    <p>10-14 days</p> Signup and view all the answers

    Which of the following characteristics should be monitored for a patient before discharge?

    <p>Temperature between 36-37.5°C</p> Signup and view all the answers

    What is the maximum treatment duration for atypical pneumonia using Azithromycin?

    <p>14 days</p> Signup and view all the answers

    Which treatment should be given for a patient at risk for Pseudomonas in CAP-MR?

    <p>IV antipneumococcal/antipseudomonal B-lactam plus extended macrolide and aminoglycoside</p> Signup and view all the answers

    What could be a reason for a lack of response to treatment of CAP?

    <p>Inappropriate antibiotic choice or dose</p> Signup and view all the answers

    If a patient is bacteremic, how should the duration of treatment be adjusted?

    <p>Doubled to the usual treatment duration</p> Signup and view all the answers

    For a patient with comorbidities in CAP-LR and no Pseudomonas risk, which is the preferred treatment?

    <p>Amoxicillin</p> Signup and view all the answers

    What is a potential cause for persistent fever despite appropriate treatment for CAP?

    <p>Infection is loculated in the lungs</p> Signup and view all the answers

    Study Notes

    Risk Stratification

    • Patients with any of these features are considered High Risk for Community Acquired Pneumonia (CAP) and require ICU admission:
      • Respiratory rate (RR) ≥30/min
      • Pulse rate (PR) ≥125/min
      • Temperature (T) ≥40°C or ≤36°C
      • Systolic blood pressure (SBP) <90mmHg or Diastolic blood pressure (DBP) ≤60mmHg
      • Altered mental status with acute onset
      • Suspected aspiration
      • Unstable co-morbid conditions
      • Chest X-ray findings: multilobar pleural effusion, abscess
    • If patients present with Severe sepsis or septic shock they are also considered High Risk for CAP and require ICU admission.
    • Patients with either High or Moderate risk CAP require a ward admission.

    Etiology/Pathogens

    • Low-risk pathogens are the most common etiologies of CAP. These are:
      • Streptococcus pneumoniae
      • Haemophilus influenzae
      • Chlamydophila pneumoniae
      • Mycoplasma pneumoniae
      • Moraxella catarrhalis
      • Enteric gram-negative bacilli (in those with co-morbid illness)
    • Moderate risk pathogens are those found in Low-risk group plus:
      • Legionella pneumophila
      • Anaerobes (in individuals with aspiration risk)
    • High-risk pathogens are those found in Moderate-risk group plus:
      • Staphylococcus aureus
      • Pseudomonas aeruginosa

    Clinical Manifestation

    • CAP most commonly presents with:
      • Fever
      • Tachycardia
      • Chills and sweats
      • Non-productive to productive cough with different secretions
      • Pleuritic chest pain
      • Nausea, vomiting, or diarrhea
      • Fatigue, headache, myalgia, arthralgia
    • Physically, patients may present with:
      • Inability to speak in full sentences
      • Increased respiratory rate
      • Use of accessory muscles of respiration
      • Increased or decreased tactile fremitus
      • Dull to flat percussion note
      • Crackles

    Diagnostics

    • Chest X-ray is the best initial test.
    • Sputum gram stain and culture help identify the pathogen.
    • Urinary antigen tests are helpful in detecting pneumococcal and Legionella antigens.
    • Polymerase chain reaction tests are used to detect specific DNA sequences, such as bacterial or viral DNA.
    • Serology, a test that detects antibodies, may also be helpful in identifying the pathogen and determining the course of the infection.
    • Biomarkers such as C-reactive protein (CRP) and procalcitonin (PCT) are useful in the following:
      • Identification of worsening disease or treatment failure.
      • Distinguishing bacterial from viral infections.
      • Determining the need for antibacterial therapy.
      • Making decisions about when to discontinue treatment.

    Pathology

    • The typical histopathological changes during bacterial pneumonia are:
      • Edema: The initial phase where the lung tissue swells.
      • Red Hepatization: The stage where the lung becomes red and firm due to an influx of red blood cells and fibrin.
      • Gray Hepatization: The stage where the lung tissue turns gray due to the accumulation of neutrophils and cellular debris.
      • Resolution: The final stage where the inflammation resolves, and the lung tissue returns to its normal state.
    • Edema is rare in biopsy samples.
    • The resolution phase corresponds to successful containment of the infection and improved gas exchange.
    • The dominant cell in each stage is:
      • Edema (initial): Bacteria
      • Red Hepatization: RBCs
      • Gray Hepatization: Neutrophils
      • Resolution (final): Macrophages
    • Different types of pneumonia present with unique radiograph patterns:
      • Bacterial CAP: Lobar pneumonia
      • Nosocomial Pneumonia: Bronchopneumonia
      • Viral, Pneumocystis pneumonia: Interstitial pneumonia

    Treatment Based on CAP Guidelines 2016

    • Low-risk:
      • No co-morbid illness:
        • Amoxicillin (drug of choice)
        • Extended macrolides (Azithromycin, Clarithromycin)
      • Stable co-morbid illness:
        • B-lactam/BLIC combination (Co-amoxiclav, Sultamicillin), or
        • 2nd gen Cephalosporins (Cefuroxime)
          • Extended macrolides
    • Moderate-risk:
      • IV non-antipseudomonal B-lactam (Ampicillin-sulbactam, Ceftriaxone, Ertapenem) PLUS either extended macrolide or fluoroquinolone (Levofloxacin, Moxifloxacin)
      • If no risk of Pseudomonas:
        • IV non-antipseudomonal B-lactam (BLIC, Cephalosporins, Carbapenem) PLUS IV Extended macrolide or Fluoroquinolone
      • If risk of Pseudomonas:
        • IV antipneumococcal/antipseudomonal B-lactam (Pip-Tazo, Cefepime, Meropenem, Imipenem-Cilastatin) PLUS extended macrolide and aminoglycoside (gentamicin, amikacin) or
        • IV antipneumococcal + antipseudomonal B-lactam (BLIC, Cephalosporins or Carbapenem) PLUS IV ciprofloxacin or IV levofloxacin
    • High-risk:
      • If MRSA is suspected, add any of the following:
        • Vancomycin, Linezolid or Clindamycin
    • Response to Treatment:
      • 1 week: Fever should have resolved.
      • 4 weeks: Chest pain and sputum production should have substantially reduced.
      • 6 weeks: Cough and breathlessness should have substantially reduced.
      • 3 months: Most symptoms should have resolved; fatigue may still be present.
      • 6 months: Most people will feel back to normal.
    • Lack of Response to Treatment:
      • Resistant pathogen
      • Sequestered focus (Lung abscess or empyema)
      • Wrong treatment
      • Correct drug but wrong dose or frequency

    Duration of Antibiotic Use Based on Etiology

    • Common bacterial pneumonias:
      • 5-7 days (excluding enteric Gram-negative pathogens, S.aureus, and P.aeruginosa)
    • Enteric Gram-negative pathogens, S.aureus, and P.aeruginosa:
      • 3-5 days (azalides) for S.pneumoniae
    • Mycoplasma and Chlamydophila:
      • 10-14 days
    • Legionella:
      • 14-21 days; 10 days (azalides)
    • Shortcuts:
      • **MSSA/*Staph aureus: 10-14 days
      • Gram-negative (enteric/non-enteric): 7 days
        • If using Azithromycin, 5 days
      • Pseudomonas or MRSA/MSSA: 14 days
      • Bacteremic: Double the usual duration
      • Atypical: Double the usual duration

    CAP-HR / CAP-MR / CAP-LR

    • Always assess for MRSA in CAP-HR patients.
    • CAP-MR treatment varies based on Pseudomonas risk:
      • No risk for Pseudomonas: IV non-antipseudomonal B-lactam (Ampicillin-sulbactam, Ceftriaxone, Ertapenem) + Extended macrolide/ Fluoroquinolone (Levofloxacin, Moxifloxacin)
      • Risk for Pseudomonas: IV antipneumococcal/antipseudomonal B-lactam (Pip-Tazo, Cefepime, Meropenem, Imipenem-Cilastatin) + extended macrolide and aminoglycoside (gentamicin, amikacin)
    • CAP-LR treatment depends on co-morbidity:
      • No co-morbid illness: Amoxicillin (drug of choice); Extended Macrolides (Azithromycin, Clarithromycin).
      • Stable co-morbid illness: B-lactam/BLIC combination (Co-amoxiclav, Sultamicillin), or 2nd gen Cephalosporins (Cefuroxime) + Extended macrolides

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Related Documents

    Description

    This quiz assesses the knowledge of risk stratification for Community Acquired Pneumonia (CAP). Focused on identifying high-risk features and understanding pathogen etiologies, the quiz will enhance your understanding necessary for patient management. Suitable for medical students and healthcare professionals.

    More Like This

    CAP Oath Flashcards
    8 questions

    CAP Oath Flashcards

    MatchlessAltoSaxophone avatar
    MatchlessAltoSaxophone
    Co-Morbid Illness in Low-Risk CAP Patients
    40 questions
    Use Quizgecko on...
    Browser
    Browser